{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T17:16:56Z","timestamp":1742923016440,"version":"3.40.3"},"publisher-location":"New York, NY","reference-count":27,"publisher":"Springer US","isbn-type":[{"type":"print","value":"9781071630358"},{"type":"electronic","value":"9781071630365"}],"license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023]]},"DOI":"10.1007\/978-1-0716-3036-5_22","type":"book-chapter","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T13:24:05Z","timestamp":1680182645000},"page":"313-325","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Exons 45\u201355 Skipping Using Antisense Oligonucleotides in Immortalized Human DMD Muscle Cells"],"prefix":"10.1007","author":[{"given":"Merry","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,31]]},"reference":[{"issue":"6","key":"22_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/0092-8674(87)90579-4","volume":"51","author":"EP Hoffman","year":"1987","unstructured":"Hoffman EP, Brown RH Jr, Kunkel LM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51(6):919\u2013928. https:\/\/doi.org\/10.1016\/0092-8674(87)90579-4","journal-title":"Cell"},{"issue":"5","key":"22_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/jcsm.12245","volume":"8","author":"MC Walter","year":"2017","unstructured":"Walter MC, Reilich P (2017) Recent developments in Duchenne muscular dystrophy: facts and numbers. J Cachexia Sarcopenia Muscle 8(5):681\u2013685. https:\/\/doi.org\/10.1002\/jcsm.12245","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"1","key":"22_CR3","first-page":"54","volume":"49","author":"AH Beggs","year":"1991","unstructured":"Beggs AH, Hoffman EP, Snyder JR et al (1991) Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet 49(1):54\u201367","journal-title":"Am J Hum Genet"},{"issue":"1","key":"22_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2006.09.016","volume":"36","author":"N Deconinck","year":"2007","unstructured":"Deconinck N, Dan B (2007) Pathophysiology of Duchenne muscular dystrophy: current hypotheses. Pediatr Neurol 36(1):1\u20137. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2006.09.016","journal-title":"Pediatr Neurol"},{"issue":"3","key":"22_CR5","first-page":"184","volume":"31","author":"W Klingler","year":"2013","unstructured":"Klingler W, Jurkat-Rott K, Lehmann-Horn F et al (2013) The role of fibrosis in Duchenne muscular dystrophy. Acta Myol 31(3):184\u2013195","journal-title":"Acta Myol"},{"issue":"1","key":"22_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/0888-7543(88)90113-9","volume":"2","author":"AP Monaco","year":"1988","unstructured":"Monaco AP, Bertelson CJ, Liechti-Gallati S et al (1988) An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. Genomics 2(1):90\u201395. https:\/\/doi.org\/10.1016\/0888-7543(88)90113-9","journal-title":"Genomics"},{"issue":"12","key":"22_CR7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/s1474-4422(03)00585-4","volume":"2","author":"F Muntoni","year":"2003","unstructured":"Muntoni F, Torelli S, Ferlini A (2003) Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2(12):731\u2013740. https:\/\/doi.org\/10.1016\/s1474-4422(03)00585-4","journal-title":"Lancet Neurol"},{"issue":"12","key":"22_CR8","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1002\/humu.21114","volume":"30","author":"KM Flanigan","year":"2009","unstructured":"Flanigan KM, Dunn DM, von Niederhausern A et al (2009) Mutational spectrum of DMD mutations in dystrophinopathy patients: application of modern diagnostic techniques to a large cohort. Hum Mutat 30(12):1657\u20131666. https:\/\/doi.org\/10.1002\/humu.21114","journal-title":"Hum Mutat"},{"issue":"3","key":"22_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000008089","volume":"42","author":"M Yazaki","year":"1999","unstructured":"Yazaki M, Yoshida K, Nakamura A et al (1999) Clinical characteristics of aged Becker muscular dystrophy patients with onset after 30 years. Eur Neurol 42(3):145\u2013149. https:\/\/doi.org\/10.1159\/000008089","journal-title":"Eur Neurol"},{"issue":"3","key":"22_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.17305\/bjbms.2015.636","volume":"15","author":"E Le Rumeur","year":"2015","unstructured":"Le Rumeur E (2015) Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies. Bosn J Basic Med Sci 15(3):14\u201320. https:\/\/doi.org\/10.17305\/bjbms.2015.636","journal-title":"Bosn J Basic Med Sci"},{"issue":"1","key":"22_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrneurol.2017.148","volume":"14","author":"C Rinaldi","year":"2018","unstructured":"Rinaldi C, Wood MJA (2018) Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol 14(1):9\u201321. https:\/\/doi.org\/10.1038\/nrneurol.2017.148","journal-title":"Nat Rev Neurol"},{"key":"22_CR12","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","volume":"87","author":"MM Evers","year":"2015","unstructured":"Evers MM, Toonen LJ, van Roon-Mom WM (2015) Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv Drug Deliv Rev 87:90\u2013103. https:\/\/doi.org\/10.1016\/j.addr.2015.03.008","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"22_CR13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1080\/14712598.2017.1271872","volume":"17","author":"EH Niks","year":"2017","unstructured":"Niks EH, Aartsma-Rus A (2017) Exon skipping: a first in class strategy for Duchenne muscular dystrophy. Expert Opin Biol Ther 17(2):225\u2013236. https:\/\/doi.org\/10.1080\/14712598.2017.1271872","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"22_CR14","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1517\/14712598.2012.693469","volume":"12","author":"T Yokota","year":"2012","unstructured":"Yokota T, Duddy W, Echigoya Y et al (2012) Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients? Expert Opin Biol Ther 12(9):1141\u20131152. https:\/\/doi.org\/10.1517\/14712598.2012.693469","journal-title":"Expert Opin Biol Ther"},{"issue":"11","key":"22_CR15","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1038\/mt.2010.186","volume":"18","author":"Y Aoki","year":"2010","unstructured":"Aoki Y, Nakamura A, Yokota T et al (2010) In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse. Mol Ther 18(11):1995\u20132005. https:\/\/doi.org\/10.1038\/mt.2010.186","journal-title":"Mol Ther"},{"issue":"3","key":"22_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3233\/JND-170233","volume":"4","author":"N Wein","year":"2017","unstructured":"Wein N, Vulin A, Findlay AR et al (2017) Efficient skipping of single exon duplications in DMD patient-derived cell lines using an antisense oligonucleotide approach. J Neuromuscul Dis 4(3):199\u2013207. https:\/\/doi.org\/10.3233\/JND-170233","journal-title":"J Neuromuscul Dis"},{"key":"22_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/978-1-4939-6817-6_17","volume":"1565","author":"R Maruyama","year":"2017","unstructured":"Maruyama R, Echigoya Y, Caluseriu O et al (2017) Systemic delivery of Morpholinos to skip multiple exons in a dog model of Duchenne muscular dystrophy. Methods Mol Biol 1565:201\u2013213. https:\/\/doi.org\/10.1007\/978-1-4939-6817-6_17","journal-title":"Methods Mol Biol"},{"key":"22_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1756286418776932","volume":"11","author":"CD Wurster","year":"2018","unstructured":"Wurster CD, Ludolph AC (2018) Antisense oligonucleotides in neurological disorders. Ther Adv Neurol Disord 11:1\u201319. https:\/\/doi.org\/10.1177\/1756286418776932","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"22_CR19","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/humu.20918","volume":"30","author":"A Aartsma-Rus","year":"2009","unstructured":"Aartsma-Rus A, Fokkema I, Verschuuren J et al (2009) Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. Hum Mutat 30(3):293\u2013299. https:\/\/doi.org\/10.1002\/humu.20918","journal-title":"Hum Mutat"},{"issue":"2","key":"22_CR20","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/humu.20428","volume":"28","author":"C B\u00e9roud","year":"2007","unstructured":"B\u00e9roud C, Tuffery-Giraud S, Matsuo M et al (2007) Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat 28(2):196\u2013202. https:\/\/doi.org\/10.1002\/humu.20428","journal-title":"Hum Mutat"},{"issue":"34","key":"22_CR21","doi-asserted-by":"publisher","first-page":"13763","DOI":"10.1073\/pnas.1204638109","volume":"109","author":"Y Aoki","year":"2012","unstructured":"Aoki Y, Yokota T, Nagata T et al (2012) Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci U S A 109(34):13763\u201313768. https:\/\/doi.org\/10.1073\/pnas.1204638109","journal-title":"Proc Natl Acad Sci U S A"},{"key":"22_CR22","doi-asserted-by":"publisher","unstructured":"Dzierlega K, Yokota T (2020) Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy. Gene Ther. https:\/\/doi.org\/10.1038\/s41434-020-0156-6","DOI":"10.1038\/s41434-020-0156-6"},{"issue":"4","key":"22_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/jpm7040013","volume":"7","author":"Q Nguyen","year":"2017","unstructured":"Nguyen Q, Yokota T (2017) Immortalized muscle cell model to test the exon skipping efficacy for Duchenne muscular dystrophy. J Pers Med 7(4):13. https:\/\/doi.org\/10.3390\/jpm7040013","journal-title":"J Pers Med"},{"key":"22_CR24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/2044-5040-1-34","volume":"1","author":"K Mamchaoui","year":"2011","unstructured":"Mamchaoui K, Trollet C, Bigot A et al (2011) Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders. Skelet Muscle 1:34. https:\/\/doi.org\/10.1186\/2044-5040-1-34","journal-title":"Skelet Muscle"},{"issue":"12","key":"22_CR25","doi-asserted-by":"publisher","first-page":"8174","DOI":"10.1093\/nar\/gku512","volume":"42","author":"T Shimo","year":"2014","unstructured":"Shimo T, Tachibana K, Saito K et al (2014) Design and evaluation of locked nucleic acid-based splice-switching oligonucleotides in vitro. Nucleic Acids Res 42(12):8174\u20138187. https:\/\/doi.org\/10.1093\/nar\/gku512","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"22_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012239","volume":"5","author":"T Saito","year":"2010","unstructured":"Saito T, Nakamura A, Aoki Y et al (2010) Antisense PMO found in dystrophic dog model was effective in cells from exon 7-deleted DMD patient. PLoS One 5(8):e12239. https:\/\/doi.org\/10.1371\/journal.pone.0012239","journal-title":"PLoS One"},{"issue":"11","key":"22_CR27","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/j.ymthe.2019.07.012","volume":"27","author":"Y Echigoya","year":"2019","unstructured":"Echigoya Y, Lim KRQ, Melo D et al (2019) Exons 45-55 skipping using mutation-tailored cocktails of antisense Morpholinos in the DMD gene. Mol Ther 27(11):2005\u20132017. https:\/\/doi.org\/10.1016\/j.ymthe.2019.07.012","journal-title":"Mol Ther"}],"container-title":["Methods in Molecular Biology","Skeletal Muscle Stem Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3036-5_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T13:29:40Z","timestamp":1680182980000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3036-5_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"ISBN":["9781071630358","9781071630365"],"references-count":27,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3036-5_22","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"31 March 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}